References

[1] The Biosimilars Council and Association for Accessible Medicines, 2017, The New Frontier for Improved Access to Medicines: Biosimilars & Interchangeable Biologic Products.

 

[2] IQVIA MIDAS MAT, Q4 2017

 

[3] Mulcahy, Hlavka, & Case, 2017, Biosimilar Cost Savings in the United States, RAND Corporation.

 

[4] Deloitte, 2016, Winning with Biosimilars. Opportunities in Global Markets.

 

[5] CSIRO, 2017, Medical Technologies and Pharmaceuticals: A Roadmap for unlocking future growth opportunities for Australia.I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

 

[6] U.S. Food & Drug Administration, 2018, Biological Product Definitions.

 

[8] Blackstone & Fuhr Joseph Jr, 2013, The Economics of Biosimilars, American Health & Drug Benefits, 6(8): 469-478

 

[9] EvaluatePharma, 2017, World Preview 2017, Outlook to 2022, 10th Edition.

 

[10] AbbVie, 2017, AbbVie Reports Third-Quarter 2017 Financial Results, available at http://investors.abbvie.com

 

[11] Abrahao-Machado & Scapulatempo-Neto, 2016, HER2 Testing in Gastric Cancer: An Update, World Journal of Gastroenterology, 22(19)

 

[12] Metastatic Breast Cancer Network, Incidence and Incidence Rates, mbcn.org [accessed: April 2018]

 

[13] World Health Organization: International Agency for Research on Cancer, GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012

 

[14] World Health Organization, 2016, Global Report on Psoriasis.

 

[15] Rachakonda T, Schupp C, & Armstrong A, 2014, Psoriasis Prevalence Among Adults in the United States, Journal of the American Academy of Dermatology, 70(3).

 

[16] Cross et al., 2014, The Global Burden of Rheumatoid Arthritis: Estimates from the Global Burden of Disease 2010 Study, Annals of the rheumatic diseases, 73(7)

 

[17] Crohn’s & Colitis Foundation, 2016, crohnscolitisfoundation.org [accessed April 2018]

 

[18] Simoes et al., 2015, Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics, The Journal of Infectious Diseases, 211(Suppl 1): S1-S20

 

[19] International Osteoporosis Foundation, Epidemiology, iofbonehealth.org [accessed: April 2018]